Y-mAbs Therapeutics (YMAB) Tops Q3 EPS by 1c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.45 million versus the consensus estimate of $20.97 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Accenture downgraded by TD Cowen on AI concerns